Glenmark Pharmaceuticals Ltd Share Price

Pharmaceuticals

NSE: GLENMARK Mid Cap ISIN: INE935A01035

As on 21 November 2025 at 13:31 IST

₹1,895.90

+ 17.90

(0.95%)

Sell Buy

Glenmark Pharmaceuticals Q1 FY26 Results:

Profit for the period declined 86.21% to ₹46.97 crores in Q1 FY26, from ₹340.23 crores in Q1 FY25. Total income for the quarter increased 0.46% year-on-year to ₹3290.88 crores from ₹3275.67 crores.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd is a global pharmaceutical company. It operates in the pharmaceutical sector, with a strong presence in respiratory and oncology therapy areas. The company was founded in the year 1977 by Gracias Saldanha and working in the business for decades. The headquarters of the company is located in Mumbai, India. Its main products span various therapeutic areas, including respiratory, dermatology, and oncology. The company is known for its formulations in these segments, which are marketed globally. Some of the company’s notable products include asthma and COPD treatments. +

Over 1 Month

1.36%

Over 6 Months

30.76%

Over 1 Year

28.07%

Over 3 Years

356.21%

Glenmark Pharmaceuticals Ltd Summary

Close ₹1,878

Open ₹1,845

High ₹1,894.80

Low ₹1,842.10

Volume 12,75,173

Net Turnover (in Cr) ₹237.55

52Wk High ₹2,284.80

52Wk Low ₹1,275.50

52Wk High / Low

1,275.50

2,284.80

Glenmark Pharmaceuticals Ltd Fundamentals

Key Financial Data

Market Cap (in Cr) ₹52,997.31

EPS (TTM) 52.14

Book Value (BV) 848.31

Div. Yield 0.13 %

P/E (TTM) 347.80

Price/Book Value 2.22

Delivery % 23.34 %

Face Value 1

Key Ratios

PE Ratio 26.99

PB Ratio 1.77

EV to Sales 4.79

PEG Ratio -0.39

ROA 6.32

ROE 6.78

Debt-Equity 0.03

Net Profit Margin 17.45

Operating Profit Margin 26.24

Glenmark Pharmaceuticals Ltd Financials

Consolidated

Standalone

Yearly

Quarterly

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	13,435.46	12,653.09	13,306.90	12,471.58	10,994.15
Total Expenses	11,663.43	11,715.64	11,672.59	10,769.42	9,656.22
Profit Before Tax	1,399.21	36.49	868.45	1,441.25	1,382.47
Profit After Tax	1,047.14	-1,830.85	377.40	993.65	970.09
Operating Profit After Depreciation	1,979.09	1,453.42	1,983.89	2,000.26	1,691.04

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Fixed Assets	4,779.66	4,452.72	6,338.47	5,976.03	5,292.73
Total Non Current Assets	6,754.09	6,930.54	9,497.96	8,800.94	8,244
Total Current Assets	9,295.47	7,428.08	9,873.72	8,282.35	7,359.58
Total Assets	16,049.55	14,358.62	19,371.68	17,083.29	15,603.58
Total Shareholder's Fund	8,849.44	7,847.93	9,473.92	9,086.65	7,064.63

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash From Operating Activities	-827.60	-265.44	625.39	1,108.65	1,131.21
Net Cash Used In Investing Activities	57.99	4,386.82	-515.44	-315.73	-661.61
Net Cash Used In Financing Activities	787.05	-3,906.13	-77.46	-520.49	-441.78

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	9,582.77	9,059.14	9,206.60	8,756.21	7,964.17
Total Expenses	7,249.59	7,128.73	7,138.86	6,849.10	6,094.31
Profit Before Tax	2,154.02	7,000.75	1,571.87	2,337.45	1,943.76
Profit After Tax	1,610.35	5,167.29	1,208.77	1,997.79	1,649.45
Operating Profit After Depreciation	2,381.92	2,207.53	2,274.56	2,143.15	2,135.76

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Fixed Assets	2,012.40	1,778.41	1,759.21	1,760.19	1,760.58
Total Non Current Assets	23,255.61	22,732.92	20,200.75	18,511.56	15,708.40
Total Current Assets	4,777.67	4,681.47	4,385.18	4,402.93	4,909.12
Total Assets	28,033.28	27,414.39	24,585.92	22,914.48	20,617.52
Total Shareholder's Fund	24,503.96	22,970.62	17,877.46	16,738.59	14,809.51

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash From Operating Activities	588.80	-495.45	1,474.06	1,216.07	1,243.42
Net Cash Used In Investing Activities	-489.90	3,197.17	-431.52	-897.02	-1,235.19
Net Cash Used In Financing Activities	-95.41	-2,666.45	-978.50	-305.12	-80.79

Particulars (in ₹ Cr.)	2025-09	2025-06	2025-03	2024-12	2024-09
Total Revenue	6,046.87	3,264.44	3,256.21	3,387.55	3,433.80
Total Expenses	3,687.32	2,683.92	2,695.18	2,787.32	2,831.88
Profit Before Tax	967.40	95.57	7.98	456.33	472.58
Profit After Tax	610.43	46.97	4.38	348.03	354.49
Operating Profit after Depreciation	2,560.18	606.96	572.72	631.36	641.34

Particulars (in ₹ Cr.)	2025-09	2025-06	2025-03	2024-12	2024-09
Total Revenue	1,538.66	2,394.93	2,009.49	2,251.28	2,636.10
Total Expenses	1,716.66	1,666.77	1,668.97	1,757.36	1,857.47
Profit Before Tax	-906.36	401.17	181.14	559.49	795.06
Profit After Tax	-739.19	330.23	147.76	413.80	595.06
Operating Profit after Depreciation	107.76	797.50	428.97	623.11	861.71

Glenmark Pharmaceuticals Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 1,848.47

S2 1,818.93

S3 1,795.77

Pivot 1,871.63

R1 1,901.17

R2 1,924.33

R3 1,953.87

Moving Average

20 SMA 1,849.08

50 SMA 1,933.53

100 SMA 1,972.56

200 SMA 1,715.28

Glenmark Pharmaceuticals Ltd Corporate Actions

Glenmark Pharmaceuticals Ltd

₹2.5/Share

Announcement Date 03 Oct 2025

Record Date 03 Oct 2025

Div Yield 250%

AGM Date: 24 Sep 2021

AGM 24/09/2021 Proceedings and Scrutinizer''s Report of the 43rd Annual General Meeting (AGM) of Glenmark Pharmaceuticals Limited (''the Company'') held on September 24, 2021 (As Per BSE Announcement Dated 24.09.2021)

AGM Date: 27 Sep 2022

AGM 27/09/2022 Pursuant to Regulation 47 read with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith copies of newspaper advertisement published in Financial Express (English) and Loksatta (Marathi) which includes the following information: Intimation of 44th AGM of the Company to be held through video conferencing / other audio-visual means and confirmation of email dispatch of Notice of AGM and Annual Report for the Financial Year 2021-22. Particulars of the facility of e-voting provided to Shareholders of the Company, to enable them to cast their votes on the resolutions proposed to be passed at the AGM. Details of Book Closure for the purpose of determining members who would be entitled to dividend if declared, at the AGM. (As Per BSE Announcement Dated 29.08.2022) Proceedings and Scrutinizer's Report of the 44th Annual General Meeting (AGM) of Glenmark Pharmaceuticals Limited ('the Company') held on September 27, 2022 (As Per BSE Announcement dated on 27.09.2022)

AGM Date: 29 Sep 2023

AGM 29/09/2023 Proceedings and Scrutinizer''s Report of the 45th Annual General Meeting of the Company held on September 29, 2023. Proceedings and Scrutinizer''s Report of the 45th Annual General Meeting of the Company held on September 29, 2023. (As Per BSE Announcement Dated on 29.09.2023)

AGM Date: 27 Sep 2024

AGM 27/09/2024 Please find attached herewith proceedings of 46th Annual General Meeting (As Per BSE Announcement Dated on: 27/09/2024)

AGM Date: 26 Sep 2025

AGM 26/09/2025 Register of Members and the Share Transfer Books of the Company will remain close from Tuesday, September 16, 2025 to Friday, September 26, 2025 (both days inclusive) for the purpose of the 47th Annual General Meeting scheduled to be held on Friday, September 26, 2025 and also for determining the names of the shareholders to whom the dividend which if declared at the Annual General Meeting will be payable. (As per BSE Announcement Dated on 22.08.2025) Notice and Explanatory Statement convening the 47th Annual General Meeting scheduled to be held on Friday, September 26, 2025 at 02:00 p.m. IST through VC / OAVM is enclosed. (As Per BSE Announcement Dated on:29.08.2025) Proceedings of the 47th AGM of the Company is enclosed. Report of Scrutinizer and Voting Result under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed. (As Per BSE Announcement Dated on:26.09.2025)

Glenmark Pharmaceuticals Ltd Peer Comparison

Company	Price	Market Cap (in Cr)
Sun Pharmaceutical Industries Ltd	₹1,777.85	₹4,26,565.77
Divis Laboratories Ltd	₹6,463.80	₹1,71,593.58
Torrent Pharmaceuticals Ltd	₹3,717.75	₹1,25,819.90
Cipla Ltd	₹1,528.95	₹1,23,504.18
Dr Reddys Laboratories Ltd	₹1,247.65	₹1,04,131.51

Glenmark Pharmaceuticals Ltd Top Mutal Funds Invested

Fund Name	AUM
Invesco India Midcap Fund	3.78%
Mahindra Manulife Multi Cap Fund	3.09%
Invesco India Large & Mid Cap Fund	2.81%
HDFC Mid Cap Fund	2.67%
HDFC Manufacturing Fund	2.24%

Glenmark Pharmaceuticals Ltd News

Glenmark Pharma gets EC nod for acne drug Winlevi in 15 European countries

Glenmark Pharmaceuticals has received marketing authorization from the European Commission (EC) for Winlevi (clascoterone 10 mg/g cream), a novel topical treatment for acne, across 15 European countries.

18 Nov 2025, 03:16 pm

Cosmo and Glenmark receive EC marketing authorization for Winlevi'

Used in treatment of acne

18 Nov 2025, 02:49 pm

Glenmark Pharma gains after Q2 PAT climbs 72% YoY to Rs 610 cr

Glenmark Pharmaceuticals advanced 1.10% to Rs 1,918.30 after the company reported a 72.3% jump in consolidated net profit to Rs 610.25 crore on 76.6% increase in revenue from operations to Rs 6,003.79 crore in Q2 FY25.

17 Nov 2025, 10:17 am

Glenmark Pharma Q2 PAT climbs 72% YoY to Rs 610 cr

Glenmark Pharmaceuticals reported a 72.3% jump in consolidated net profit to Rs 610.25 crore on 76.6% increase in revenue from operations to Rs 6,003.79 crore in Q2 FY25.

15 Nov 2025, 01:06 pm

Glenmark Pharmaceuticals Ltd spurts 2.55%, gains for third straight session

Glenmark Pharmaceuticals Ltd is quoting at Rs 1928.6, up 2.55% on the day as on 12:49 IST on the NSE. The stock is up 29.81% in last one year as compared to a 10.06% spurt in NIFTY and a 5.77% spurt in the Nifty Pharma index.

14 Nov 2025, 01:05 pm

Glenmark Pharmaceuticals Ltd Stock Analysis

Annual revenue for Glenmark Pharmaceuticals Ltd increased by 5.78% to ₹9,582.77 crore in FY 2025 from ₹9,059.14 crore in FY 2024.
Annual Net Profit for Glenmark Pharmaceuticals Ltd decreased by 68.84% to ₹1,610.35 crore in FY 2025 from ₹5,167.29 crore in FY 2024.
Promoter Shareholding in Glenmark Pharmaceuticals Ltd remains unchanged by 0.00% in the most recent quarter, from 46.65% in June 2025 to 46.65% in September 2025.
Glenmark Pharmaceuticals Ltd delivered a 1-year return of 28.07% compared to the Nifty 50, which provided a return of 12.17% as of the last trading session.
Glenmark Pharmaceuticals Ltd share price moved up by 0.95% from its previous close of INR ₹1,878. The latest Glenmark Pharmaceuticals Ltd share price is INR ₹1,895.90.
Glenmark Pharmaceuticals Ltd share price today has been at a low of 1,875.90 and a high of 1,908. Over the past 52 weeks, the Glenmark Pharmaceuticals Ltd share price has seen a low of 1,275.50 and a high of 2,284.80.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd is a global pharmaceutical company. The company's primary focus is to develop and market branded and generic formulations. It operates in the pharmaceutical sector, with a strong presence in respiratory and oncology therapy areas.
Founded by Gracias Saldanha in 1977, Glenmark has been in business for decades. The company is headquartered in Mumbai, India. Its journey began as a generic drug and active pharmaceutical ingredient manufacturer. The company has since evolved into a research-led organisation with a global footprint.
The promoters of Glenmark Pharmaceuticals include the Saldanha family at a 45.45% stake. Glenn Saldanha serves as the Chairman and Managing Director. Under his leadership, the company has expanded its reach and capabilities. To do this, it sets its focus on innovation and advanced therapies. The company also has a team of managerial promoters that includes-

Cherylann Pinto
V S Mani
B E Saldanha
Saira Ramasastry

Glenmark’s main products span various therapeutic areas, including respiratory, dermatology, and oncology. The company is known for its formulations in these segments, which are marketed globally. Some of its notable products include asthma and COPD treatments. It also includes dermatological solutions and oncology drugs.
While Glenmark is a significant player in the pharmaceutical industry, it is not the largest in terms of market share. However, its innovative research and development efforts continue contributing to the sector. The promoter shareholding in Glenmark Pharmaceuticals stands at the top. This indicates a firm commitment from the founding family towards the company’s growth and strategic direction.
The registered office of Glenmark Pharmaceuticals is in Mumbai, Maharashtra. On the other hand, the registrar's office is in the Financial District, Hyderabad. Overall, the company remains a prominent name in the pharmaceutical industry, known for its commitment to research and patient care.

The vision of Glenmark Pharmaceuticals Limited

The company’s vision is centred on improving the quality of life for patients globally. This commitment drives Glenmark to explore new frontiers in medical science. It also helps it to develop therapies that address unmet medical needs. Innovation is at the heart of Glenmark’s vision. The company invests heavily in research and development to discover and create new drugs. This focus on innovation has led to several breakthrough therapies in areas such as oncology and dermatology. Glenmark believes innovation can provide patients with more effective and safer treatment options. Global reach is another key aspect of Glenmark’s vision. The company aims to expand its presence internationally. Through this, it ensures its products are available to patients worldwide. Glenmark operates in over 80 countries, with a strong presence in emerging markets. This global footprint allows the company to reach a diverse patient population and address a wide range of healthcare needs. Sustainability is a crucial part of Glenmark’s vision. The company is committed to conducting its business in an environmentally responsible manner. This includes minimising waste and conserving natural resources. Glenmark believes that sustainable practices are crucial for the planet's long-term health. Patient-centricity is at the core of Glenmark’s vision. The company is committed to understanding the needs and challenges faced by patients. It focuses on developing solutions that enhance their quality of life. The company is committed to understanding the needs and challenges faced by patients. It also focuses on developing solutions that enhance their quality of life. The company collaborates with governments, and non-profit organisations to ensure patients receive the treatments they need. This close cooperation helps improve access to essential healthcare solutions. Collaboration and partnerships play a crucial role in Glenmark’s vision. It believes that working with other organisations can speed up the development of new therapies. This approach aims to bring innovative treatments to market more quickly. Glenmark collaborates with academic institutions and pharmaceutical companies to advance its development efforts. These partnerships enable Glenmark to leverage external expertise and resources, enhancing its innovation ability. Glenmark’s vision extends to its employees as well. The company is committed to fostering a supportive work environment. It focuses on inclusivity, ensuring all employees have the opportunity to thrive. Glenmark invests in the professional development of its workforce. This provides opportunities for learning and growth. The company believes a motivated and skilled workforce is essential for achieving its vision of innovation.
Ethical business practices are a cornerstone of Glenmark’s vision. The company is dedicated to upholding the highest standards of integrity. It ensures transparency in all its operations. This includes adhering to strict regulatory requirements and ensuring the quality and safety of its products. The company also conducts business with honesty and fairness in all its dealings. Glenmark believes that ethical conduct is essential for establishing trust with patients. This commitment extends to all other stakeholders, including healthcare providers and partners.
Looking to the future, Glenmark aims to continue its journey of growth and innovation. The company is focused on expanding its product portfolio to offer a broader range of solutions. Additionally, it aims to enhance its research capabilities to meet evolving market needs. Glenmark’s vision is to be a leading global pharmaceutical company, recognized for its commitment to innovation and patient care.
The company envisions a world where innovative healthcare solutions are accessible to all. Its dedication to these principles guides its efforts to improve the quality and contribute to a healthier future.